More Company News

Arecor Therapeutics

Second AT278 trial to commence in Type II diabetes
22 Nov 2022Read More

Arecor Therapeutics

Insulin product patents granted in Japan and South Korea
22 Nov 2022Read More

Arecor Therapeutics

Appointment of Interim CFO
21 Nov 2022Read More

Arecor Therapeutics

Poster to be presented at IBD Nordic Conference
17 Nov 2022Read More

Arecor Therapeutics

Strategy to focus on late-stage pipeline regulatory approvals
15 Nov 2022Read More

Arecor Therapeutics

Top line data from FRUTIGA China Phase III in 2L gastric cancer
14 Nov 2022Read More

Arecor Therapeutics

Exclusive Specialty Hospital formulation collaboration
10 Nov 2022Read More

Arecor Therapeutics

RXC004 Phase II combination arms to open enrolment
10 Nov 2022Read More

Arecor Therapeutics

Q322 results
09 Nov 2022Read More

Arecor Therapeutics

Result of the Open Offer
08 Nov 2022Read More

1 2 3 4 … 71
Return to Arecor Therapeutics
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).